


EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
2. Authorization for this examiner's amendment was given in a telephone interview with Mr. Sunil Raval on January 15, 2010 and January 19, 2010.
3. The application has been amended as follows:

A. Claim 1 has been amended to read as follows:

--1. (Currently amended) A compound of the formula (I):



wherein R' represents an anti-epileptic drug moiety or an anticonvulsive drug moiety; wherein the drug moiety is selected from the group consisting of phenytoin and other hydantoins; phenobarbital and other barbiturates; primidone, carbamazepine and oxacarbamazepine, valproic acid or its derivatives; oxazolidines; benzo-diazepines; felbamate; gabapentin; lamotrigine; vigabatrin and adrenocorticotrophic hormone (ACTH); γ -aminobutyric acid and kynurenic acid; and

R is selected from the group consisting of -CH₂OH, -CHO and -CH₂NH₂; or pharmaceutically acceptable salts thereof. --.

B. Claim 2 has been cancelled.

C. At claim 3, the first line has been amended to read as follows:


--3. (Previously presented) The compound according to claim 1,--.

D. Claim 4 has been amended to read as follows:

--4. (Amended) The compound according to claim 1, wherein R' represents a moiety of γ -aminobutyric acid and kynurenic acid. --.

E. Claim 8 has been amended to read as follows:

--8. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of the formula (I):




and a pharmaceutically acceptable carrier or excipient, wherein R' represents an anti-epileptic drug moiety or an anticonvulsive drug moiety; wherein the drug moiety is selected from the group consisting of phenytoin and other hydantoin; phenobarbital and other barbiturates; primidone, carbamazepine; and oxacarbamazepine, valproic acid or its derivatives; oxazolidines; benzo-diazepines; felbamate; gabapentin; lamotrigine; vigabatrin and adrenocorticotrophic hormone (ACTH); γ -aminobutyric acid and kynurenic acid; and

R is selected from the group consisting of $-CH_2OH$, $-CHO$ and $-CH_2NH_2$; or pharmaceutically acceptable salts thereof. --.

F. Claim 12 has been amended to read as follows:

--12. (Currently amended) A method of treatment of epilepsy comprising administering to an individual in need thereof a therapeutically effective amount of a compound of the formula (I):




wherein R' represents an anti-epileptic drug moiety or an anticonvulsive drug moiety; wherein the drug moiety is selected from the group consisting of phenytoin and other hydantoins; phenobarbital and other barbiturates; primidone, carbamazepine and oxacarbamazepine, valproic acid or its derivatives; oxazolidines; benzo-diazepines; felbamate; gabapentin; lamotrigine; vigabatrin and adrenocorticotrophic hormone (ACTH); γ -aminobutyric acid and kynurenic acid; and

R is selected from the group consisting of -CH₂OH, -CHO and -CH₂NH₂; or pharmaceutically acceptable salts thereof. --.

G. Claim 16 has been amended to read as follows:

--16. (Amended) A method for preventing epileptic episodes, alleviating epileptic episodes and/or reducing side effects of anti-epileptic drugs comprising the step of administering to a subject a therapeutically effective amount of a compound of the formula (I):



wherein R' represents an anti-epileptic drug moiety or an anticonvulsive drug moiety; wherein the drug moiety is selected from the group consisting of phenytoin and other hydantoins; phenobarbital and other barbiturates; primidone, carbamazepine and oxacarbamazepine, valproic acid or its derivatives; oxazolidines; benzo-diazepines; felbamate; gabapentin; lamotrigine; vigabatrin and adrenocorticotrophic hormone (ACTH); γ -aminobutyric acid and kynurenic acid; and

R is selected from the group consisting of $-\text{CH}_2\text{OH}$, $-\text{CHO}$ and $-\text{CH}_2\text{NH}_2$; or pharmaceutically acceptable salts thereof. --.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

4. Based upon the response filed November 2, 2009, the rejections under 35 U.S.C. 112, 2nd paragraph and 35 U.S.C. 102(b) based upon Dolina et al. and Dakshinamurti et al. are withdrawn.
5. In order to meet the requirements of 35 U.S.C. 112, 1st paragraph, claims 1, 4, 8, 12, and 16 have been amended. At pages 5 and 6 of the specification, support is found.
6. Claim 4 has been amended to improve the clarity.
7. Claims 16 and 18 have been rejoined with the invention of Group I.
8. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna N. Davis whose telephone number is 571-272-0682.
10. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Zinna Northington Davis/
Zinna Northington Davis
Primary Examiner
Group 1600-AU 1625